Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/Ib trial of durvalumab (MEDI4736), tremelimumab + cetuximab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (OBERON)

Trial Profile

Phase I/Ib trial of durvalumab (MEDI4736), tremelimumab + cetuximab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (OBERON)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Jan 2019

At a glance

  • Drugs Cetuximab (Primary) ; Durvalumab (Primary) ; Tremelimumab (Primary)
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Adverse reactions
  • Acronyms OBERON
  • Most Recent Events

    • 15 Jan 2019 Recruitment completion is expected on 14 Jan 2021 according to ISRCTN: Current Controlled Trials.
    • 15 Jan 2019 Status changed from not yet recruiting to recruiting.
    • 17 Nov 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top